Paratek Pharmaceuticals Statistics Share Statistics Paratek Pharmaceuticals has 57.32M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 57.32M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 50.11M Failed to Deliver (FTD) Shares 110,528 FTD / Avg. Volume 18.43%
Short Selling Information The latest short interest is 2.75M, so 4.81% of the outstanding
shares have been sold short.
Short Interest 2.75M Short % of Shares Out 4.81% Short % of Float 5.83% Short Ratio (days to cover) 6.27
Valuation Ratios The PE ratio is -1.6 and the forward
PE ratio is null.
Paratek Pharmaceuticals's PEG ratio is
0.39.
PE Ratio -1.6 Forward PE n/a PS Ratio 0.67 Forward PS n/a PB Ratio -0.59 P/FCF Ratio -1.54 PEG Ratio 0.39
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Paratek Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.66,
with a Debt / Equity ratio of -1.51.
Current Ratio 3.66 Quick Ratio 3.22 Debt / Equity -1.51 Debt / EBITDA -5.76 Debt / FCF -3.9 Interest Coverage -2.55
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $562.64K Profits Per Employee $-237.19K Employee Count 268 Asset Turnover 0.87 Inventory Turnover 1.39
Taxes Income Tax 57K Effective Tax Rate -0.09%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 1.7, so Paratek Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.7 52-Week Price Change n/a 50-Day Moving Average 2.2 200-Day Moving Average 2.07 Relative Strength Index (RSI) 59.19 Average Volume (20 Days) 599,679
Income Statement In the last 12 months, Paratek Pharmaceuticals had revenue of 150.79M
and earned -63.57M
in profits. Earnings per share was -1.17.
Revenue 150.79M Gross Profit 127.73M Operating Income -46.21M Net Income -63.57M EBITDA -44.9M EBIT -45.39M Earnings Per Share (EPS) -1.17
Full Income Statement Balance Sheet The company has 34.25M in cash and 258.41M in
debt, giving a net cash position of -224.17M.
Cash & Cash Equivalents 34.25M Total Debt 258.41M Net Cash -224.17M Retained Earnings -930.45M Total Assets 145.79M Working Capital -97.39M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -66.14M
and capital expenditures -36K, giving a free cash flow of -66.18M.
Operating Cash Flow -66.14M Capital Expenditures -36K Free Cash Flow -66.18M FCF Per Share -1.22
Full Cash Flow Statement Margins Gross margin is 84.71%, with operating and profit margins of -30.65% and -42.16%.
Gross Margin 84.71% Operating Margin -30.65% Pretax Margin -42.12% Profit Margin -42.16% EBITDA Margin -29.78% EBIT Margin -30.65% FCF Margin -43.89%
Dividends & Yields PRTK does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for PRTK.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Oct 31, 2014. It was a
backward
split with a ratio of 1:12.
Last Split Date Oct 31, 2014 Split Type backward Split Ratio 1:12
Scores Altman Z-Score -9.7 Piotroski F-Score 4
